27806641|t|Empty Capsids and Macrophage Inhibition / Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic Mice
27806641|a|Gene therapy has potential to treat rheumatic diseases; however, the presence of macrophages in the joint might hamper adeno-associated viral vector -mediated gene delivery. Here we demonstrate that in arthritic, but also in healthy, mice administration of agents that influence macrophage activity / number and/or addition of empty decoy capsids substantially improve the efficacy of recombinant adeno-associated viral vector 5 transgene expression in the joint. Pretreatment with triamcinolone or clodronate liposomes improved luciferase expression over a period of 4 weeks. Similar results were seen when empty decoy capsids were added to full genome containing capsids in a 5:1 ratio. In a study to assess the duration of expression as well as to investigate the combination of these two approaches, we observed a synergistic enhancement of gene expression, sustained for at least 12 weeks. The enhancement of gene expression was independent of the route of administration of triamcinolone (intra-articular or intramuscular). In healthy mice it was demonstrated that the combination improved expression of the transgene significantly, in a serotype independent manner. These data have implications for future applications of gene therapy to the joint and for other tissues with an abundance of macrophages.
27806641	6	13	Capsids	T017	UMLS:C0006933
27806641	18	28	Macrophage	T017	UMLS:C0024432
27806641	61	65	rAAV	T103	UMLS:C1520007
27806641	66	75	Transgene	T017	UMLS:C0282641
27806641	76	86	Expression	T038	UMLS:C0017262
27806641	90	96	Joints	T082	UMLS:C0022417
27806641	117	126	Arthritic	T038	UMLS:C0003864
27806641	127	131	Mice	T204	UMLS:C0025929
27806641	132	144	Gene therapy	T058	UMLS:C0017296
27806641	162	167	treat	T058	UMLS:C0087111
27806641	168	186	rheumatic diseases	T038	UMLS:C0035435
27806641	201	209	presence	T033	UMLS:C0150312
27806641	213	224	macrophages	T017	UMLS:C0024432
27806641	232	237	joint	T082	UMLS:C0022417
27806641	251	273	adeno-associated viral	T005	UMLS:C0001417
27806641	274	280	vector	T103	UMLS:C1520007
27806641	334	343	arthritic	T038	UMLS:C0003864
27806641	366	370	mice	T204	UMLS:C0025929
27806641	371	395	administration of agents	T058	UMLS:C2348003
27806641	411	421	macrophage	T017	UMLS:C0024432
27806641	465	478	decoy capsids	T017	UMLS:C0006933
27806641	493	500	improve	T033	UMLS:C0184511
27806641	529	551	adeno-associated viral	T005	UMLS:C0001417
27806641	552	558	vector	T103	UMLS:C1520007
27806641	561	570	transgene	T017	UMLS:C0282641
27806641	571	581	expression	T038	UMLS:C0017262
27806641	589	594	joint	T082	UMLS:C0022417
27806641	614	627	triamcinolone	T103	UMLS:C0040864
27806641	631	641	clodronate	T103	UMLS:C0162357
27806641	642	651	liposomes	T103	UMLS:C0023828
27806641	652	660	improved	T033	UMLS:C0184511
27806641	661	671	luciferase	T103	UMLS:C0024075
27806641	672	682	expression	T038	UMLS:C0017262
27806641	746	759	decoy capsids	T017	UMLS:C0006933
27806641	779	785	genome	T017	UMLS:C0017428
27806641	797	804	capsids	T017	UMLS:C0006933
27806641	826	831	study	T062	UMLS:C0008972
27806641	858	868	expression	T038	UMLS:C0017262
27806641	977	992	gene expression	T038	UMLS:C0017262
27806641	1046	1061	gene expression	T038	UMLS:C0017262
27806641	1112	1125	triamcinolone	T103	UMLS:C0040864
27806641	1127	1142	intra-articular	T082	UMLS:C0442108
27806641	1146	1159	intramuscular	T082	UMLS:C0442117
27806641	1173	1177	mice	T204	UMLS:C0025929
27806641	1219	1227	improved	T033	UMLS:C0184511
27806641	1228	1238	expression	T038	UMLS:C0017262
27806641	1246	1255	transgene	T017	UMLS:C0282641
27806641	1276	1284	serotype	T170	UMLS:C0449943
27806641	1361	1373	gene therapy	T058	UMLS:C0017296
27806641	1381	1386	joint	T082	UMLS:C0022417
27806641	1401	1408	tissues	T017	UMLS:C0040300
27806641	1430	1441	macrophages	T017	UMLS:C0024432